Close

Amgen (AMGN) Receives Positive EMA CHMP Opinion on Parsabiv as Secondary Hyperparathyroidism Treatment

Go back to Amgen (AMGN) Receives Positive EMA CHMP Opinion on Parsabiv as Secondary Hyperparathyroidism Treatment